Stock Symbol:   

Stoxline Mobile
Home  |  Stock Charts  |  Showcases  |  Stock Ranks  |  Options  |  ETFs  |  Educations  |  Forex Crypto

Jasper Therapeutics, Inc. (JSPR)

0.65   -0.027 (-3.99%) 09-27 10:20
Open: 0.6712 Pre. Close: 0.677
High: 0.6712 Low: 0.6498
Volume: 125,893 Market Cap: 72(M)

Technical analysis

as of: 2023-09-27 9:47:23 AM
Short-term rate:       
Stoxline posted a NEUTRAL today, upgraded from lower rating. Current trend continues, but could change at anytime. It is not a good time to buy or sell.
Mid-term rate:       
Target: Six months: 1.31     One year: 1.67
Support: Support1: 0.62    Support2: 0.51
Resistance: Resistance1: 1.12    Resistance2: 1.42
Pivot: 0.77
Moving Average: MA(5): 0.71     MA(20): 0.86
MA(100): 1.35     MA(250): 1.3
MACD: MACD(12,26): -0.2     Signal(9): -0.2
Stochastic oscillator: %K(14,3): 10.7     %D(3): 13.8
RSI: RSI(14): 22.1
52-week: High: 3.79  Low: 0.38
Average Vol(K): 3-Month: 288 (K)  10-Days: 737 (K)

Price, moving averages and Bollinger Bands

Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and BEARISH in mid-long term.
[ JSPR ] has closed above bottom band by 9.9%. Bollinger Bands are 23% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.

Stock Price Prediction

Update at 5:00pm EST
If tomorrow: Open lower Open higher
High: 0.75 - 0.76 0.76 - 0.76
Low: 0.61 - 0.62 0.62 - 0.62
Close: 0.67 - 0.68 0.68 - 0.68

Company Description

Jasper Therapeutics, Inc., a clinical-stage biotechnology company, develops therapeutic agents for hematopoietic stem cell transplantation and gene therapies. It focuses on the development and commercialization of conditioning agents and stem cell engineering to allow expanded use of stem cell transplantation and ex vivo gene therapy, a technique in which genetic manipulation of cells is performed outside the body prior to transplantation. The company's lead product candidate is JSP191, which is in clinical development as a conditioning antibody that clears hematopoietic stem cells from bone marrow in patients prior to undergoing allogeneic stem cell therapy or stem cell gene therapy. It is also developing engineered hematopoietic stem cells product candidates to overcome key limitations of allogeneic and autologous gene-edited stem cell grafts. The company is based in Redwood City, California.

Headline News

Mon, 25 Sep 2023
Jasper Therapeutics Appoints Herb Cross As New CFO - Nasdaq

Mon, 25 Sep 2023
Jasper Therapeutics Strengthens Leadership Team with ... - Best Stocks

Mon, 25 Sep 2023
Jasper Therapeutics (JSPR) Appoints Herb Cross as CFO -

Thu, 21 Sep 2023
Powerbridge Technologies Expands Global Trade Digital Platform ... - Best Stocks

Thu, 21 Sep 2023
Jasper Therapeutics to Present New Positive Data on Briquilimab ... - GlobeNewswire

Fri, 15 Sep 2023
Jasper Therapeutics to Present at the Cantor Fitzgerald 2023 Global Healthcare Conference - Yahoo Finance

Financial Analysis

Price to Book Value: Neutral
P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.
Price to Earnings: Neutral
PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).
Discounted cash flow: Neutral
DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.
Return on Assets: Neutral
ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.
Return on Equity: Neutral
ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.
Debt to Equity: Neutral
evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.
Free Technical Analysis Charts

Stock Basics & Statistics

Exchange:  NASDAQ
Sector:  Healthcare
Industry:  Biotechnology
Shares Out. 111 (M)
Shares Float 57 (M)
% Held by Insiders 7.9 (%)
% Held by Institutions 87.6 (%)
Shares Short 1,090 (K)
Shares Short P.Month 1,010 (K)

Stock Financials

EPS -0.95
EPS Est Next Qtl 0
EPS Est This Year 0
EPS Est Next Year 0
Book Value (p.s.) 1
Profit Margin (%) 0
Operating Margin (%) 0
Return on Assets (ttm) -37.5
Return on Equity (ttm) -65.6
Qtrly Rev. Growth 0
Gross Profit (p.s.) 0
Sales Per Share 0
EBITDA (p.s.) -0.52
Qtrly Earnings Growth 0
Operating Cash Flow -46 (M)
Levered Free Cash Flow -29 (M)

Stock Valuations

PE Ratio -0.7
PEG Ratio 0
Price to Book value 0.66
Price to Sales 0
Price to Cash Flow -1.6

Stock Dividends

Dividend 0
Forward Dividend 0
Dividend Yield 0%
Dividend Pay Date Invalid DateTime.
Ex-Dividend Date Invalid DateTime.
Your Ad Here
StockChart iOS
StoxlineLite iOS
StoxlineLite iOS
OptionCalc iOS
StockChart Android
StoxlineLite Android
StoxlinePro Android
OptionCalc Android
(c) 2006-2022 | Contact us           
Data and information is provided for informational purposes only, and is not intended for trading purposes. Neither nor its data provider shall be liable for any errors or delays in the content, or for any actions taken in reliance thereon. By accessing the web site, a user agrees not to redistribute the information found therein.